This segment focuses on the research and development of precisely targeted therapies for cancer patients, addressing critical unmet needs in oncology. Nuvalent's approach involves creating innovative treatments designed to overcome the limitations of existing therapies, particularly for clinically proven kinase targets. The lead product candidates, NVL-520 and NVL-655, are designed to inhibit ROS1 and ALK fusions, respectively, even in the presence of drug-resistant mutations. Research and development activities include preclinical studies, Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of these novel inhibitors. The goal is to provide personalized treatment options that improve patient outcomes and quality of life by targeting specific genetic alterations driving cancer growth.